Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

ClinicalTrials.gov ID: NCT06655896

Public ClinicalTrials.gov record NCT06655896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multi-part, Randomized, Open-label, Assessor-blinded, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Rituximab Treatment in Participants With Severe Refractory Diffuse Cutaneous Systemic Sclerosis

Study identification

NCT ID: NCT06655896
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 96 participants

Conditions and interventions

Conditions

Scleroderma, Diffuse

Interventions

rapcabtagene autoleucel Biological
rituximab Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 28, 2024
Primary completion: Nov 29, 2028
Completion: Aug 29, 2032
Last update posted: May 12, 2026

2024 – 2032

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
UCLA	Los Angeles	California	90095	Recruiting
UCSF	San Francisco	California	94115	Recruiting
Sutter Health Network	San Pablo	California	94806	Recruiting
FL Medical Clinic Orlando Health	Zephyrhills	Florida	33542	Recruiting
Northwestern University	Chicago	Illinois	60611	Recruiting
University Of Iowa	Iowa City	Iowa	52242	Recruiting
Boston Medical Center	Boston	Massachusetts	02118	Recruiting
Michigan Med University of Michigan	Ann Arbor	Michigan	48109 5271	Recruiting
University of Minnesota	Minneapolis	Minnesota	55455	Recruiting
James Cancer Hospital	Columbus	Ohio	43210	Recruiting
Oregon Health Sciences University	Portland	Oregon	97239	Recruiting
Avera Cancer	Sioux Falls	South Dakota	57105	Recruiting
LDS Hospital	Salt Lake City	Utah	84143	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06655896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 12, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06655896 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →